AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
The Cambridge-based pharmaceutical company said the treatment improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer. Small cell lung cancer is highly aggressive, with only 15-30% of patients surviving beyond five years after diagnosis and for decades treatment for this variant has remained unchanged.
Amsterdam University’s Professor of Clinical Experimental Radiotherapy Suresh Senan said: ‘[This] is the first global Phase III immunotherapy trial to deliver significant, clinically meaningful improvement in survival in this setting, marking a breakthrough for patients with this devastating disease.’
During the trials the safety profile of Imfinzi remained consistent with no new safety signals identified. The treatment is currently approved for use in a range of countries including the US, Japan and China.
AstraZeneca shares were down 1.1% to 10,620.00 pence each in London on Friday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
